Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · IEX Real-Time Price · USD
1.93
+0.06 (3.21%)
Mar 30, 2023, 2:01 PM EDT - Market open
3.21%
Market Cap 144.09M
Revenue (ttm) 28.15M
Net Income (ttm) -19.64M
Shares Out 75.05M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 102,811
Open 1.90
Previous Close 1.87
Day's Range 1.87 - 1.94
52-Week Range 1.55 - 3.81
Beta 1.70
Analysts Buy
Price Target 5.61 (+190.67%)
Earnings Date May 9, 2023

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to ma... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 130
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2022, Stereotaxis's revenue was $28.15 million, a decrease of -19.63% compared to the previous year's $35.02 million. Losses were -$19.64 million, 62.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for STXS stock is "Buy." The 12-month stock price forecast is $5.61, which is an increase of 190.67% from the latest price.

Price Target
$5.61
(190.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening...

1 week ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q4 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 23.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Stereotaxis Reports 2022 Full Year Financial Results

ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

3 weeks ago - GlobeNewsWire

Stereotaxis to Present at Cowen 43rd Annual Health Care Conference

ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

1 month ago - GlobeNewsWire

Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023

ST. LOUIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

2 months ago - GlobeNewsWire

Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis' Genesis System

ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of p...

3 months ago - GlobeNewsWire

Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference

ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

4 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Stereotaxis Reports 2022 Third Quarter Financial Results

ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

5 months ago - GlobeNewsWire

Stereotaxis to Report Third Quarter Financial Results on November 10, 2022

ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

5 months ago - GlobeNewsWire

Stereotaxis Receives St. Louis Mayor's Innovation Award for 2022

ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded...

6 months ago - GlobeNewsWire

International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value

ST. LOUIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendanc...

6 months ago - GlobeNewsWire

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland...

7 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 19.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Stereotaxis Reports 2022 Second Quarter Financial Results

ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

8 months ago - GlobeNewsWire

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline

ST. LOUIS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significan...

8 months ago - GlobeNewsWire

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

9 months ago - GlobeNewsWire

Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter

ST. LOUIS, July 11, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark su...

9 months ago - GlobeNewsWire

Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP

16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders 16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation f...

10 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Stereotaxis Reports 2022 First Quarter Financial Results

ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

11 months ago - GlobeNewsWire

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology Denmark's only robot...

11 months ago - GlobeNewsWire

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

Stereotaxis robotic technology now in use in 25 countries Stereotaxis robotic technology now in use in 25 countries

1 year ago - GlobeNewsWire

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis

Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use s...

1 year ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research